Improved methods for quantitation of acute phase proteins in biological samples. Using monoclonal antibodies and fluorescence polarisation, we aim to develop improved quantitative analytical methods that are superior to the current clinical assays. The initial targets will be C-reactive protein (CRP) and serum amyloid precursor protein (SAP), but the technology should be readily adaptable to other serum proteins. Better assays for CRP and SAP will greatly facilitate improved clinical management ....Improved methods for quantitation of acute phase proteins in biological samples. Using monoclonal antibodies and fluorescence polarisation, we aim to develop improved quantitative analytical methods that are superior to the current clinical assays. The initial targets will be C-reactive protein (CRP) and serum amyloid precursor protein (SAP), but the technology should be readily adaptable to other serum proteins. Better assays for CRP and SAP will greatly facilitate improved clinical management of those at risk of heart attack, the single biggest contributor to healthcare costs in Australia. We further aim to adapt this technology to enable "point-of-care" assays that would help medical practitioners, especially in rural areas, to make informed diagnoses immediately.Read moreRead less
DEEP DRILLING OF THE HUMAN PLASMA PROTEOME. Like turning out city lights lets you see the faint stars more clearly - removal of high abundance proteins from human biofluids allows quantum leaps in biomarker discovery. This project will develop products that remove the biggest obstacle in proteomics - high abundance proteins (city lights). Cheap, efficient and routine removal of abundant proteins will amplify the power of ?cutting edge? proteomic technologies in the discovery of novel biomarkers ....DEEP DRILLING OF THE HUMAN PLASMA PROTEOME. Like turning out city lights lets you see the faint stars more clearly - removal of high abundance proteins from human biofluids allows quantum leaps in biomarker discovery. This project will develop products that remove the biggest obstacle in proteomics - high abundance proteins (city lights). Cheap, efficient and routine removal of abundant proteins will amplify the power of ?cutting edge? proteomic technologies in the discovery of novel biomarkers. This is possible because undiscovered low copy number biomarkers (faint stars) exist in human diagnostic fluids at levels far lower than current proteomic array detection limits.Read moreRead less